TrialEuropean journal of clinical pharmacology2013

NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.

Junichi Azuma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.